Patient Eligibility PreScreening

A Prospective, Open-Label, Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor Malignancies

Patients with any stage solid tumor malignancy will be identified and screened for study inclusion and exclusion criteria. ***Eligible patients will be counseled and consented for tissue procurement. Enrolled patients will undergo either surgical resection or core needle biopsy of their tumor, with a minimum of 1mg of tumor sterilely frozen.***

The goal of this clinical trial is to learn about TLPO cancer vaccine in cases of solid tumor malignancies. The main objectives it aims to learn about are:

- What is the time to progression/recurrence of disease after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
- What is the overall survival after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
- What are the safety characteristics of autologous TLPO using standardized criteria (Common Terminology Criteria for Adverse Events v5.0)
- Does TPLO generate an immune response?
- Determine the presence, rate, and duration of any disease control response affected by TPLO.

Please answer the following questions and provide the patient's most recent scan and oncology visit notes in order for Elios Therapeutics, LLC. to evaluate their eligibility for the Phase IIa Basket Trial. **Generally, the information needed may be downloaded from MyChart and sent to Elios Therapeutics. Please send to: sherri.daniel@eliosholdings.com**

Name:	Date of Birth:
Diagnosis:	
Date of Diagnosis:	
Disease Stage:	
Treatment(s) completed to date:	
Are you currently undergoing treatment? If yes, please describe:	
When was your most recent scan? *Please provide report.*	
When was your most recent oncologist appointment? *Please provide visit notes*.	
Is tumor tissue available? **(Tumor must be fresh frozen in a pathology lab with NO ADDITIVES or FORMALIN or PARRAFIN BLOCKS. Tumor tissue with any additives, formalin or parrafin blocks are not useable and a biopsy will be required.)**	
I understand this information is for a Phase IIa Basket Trial. I have read the information provided on clinicaltrials.gov regarding NCT06175221. Furthermore, I understand that transmission of medical documents via email is not encrypted and I assume any risk involved in the submittal. **Patient Signature:**	
Date:	